Bronchopulmonary dysplasia remains the most common serious complication of extreme prematurity, a chronic lung disease that condemns survivors to years of respiratory misery, neurodevelopmental impairment, and a lifetime of medical fragility. The condition arises because infants born before 28 weeks must use immature lungs to breathe air instead of amniotic fluid, triggering a vicious cycle of inflammation, oxidative stress, and arrested alveolar development. Systemic corticosteroids like dexamethasone blunt this destructive cascade, but their historical association with cerebral palsy and cognitive deficits has made clinicians rightfully cautious. The BPDe2022 tool, developed from a massive NIH-funded cohort, revolutionized risk stratification by crunching gestational age, birth weight, race, sex, and crucially, the mode and duration of respiratory support on specific postnatal days. It outputs a percentage risk of developing moderate-to-severe BPD or death, updated dynamically as the infant’s clinical trajectory evolves. Until now, however, no one had tested whether merely having this number would change physician behavior.

The new initiative, dubbed “Right Baby, Right Time,” spanned multiple academic and community NICUs and embedded the BPDe2022 calculation into a structured clinical decision-support framework. Instead of leaving the risk score as an abstract figure in a research paper, the team built automated weekly reports that flagged infants crossing a predetermined risk threshold—specifically, a greater than 60% likelihood of BPD or death at 36 weeks corrected age. When a neonate crossed that line, a multidisciplinary huddle was triggered, prompting a standardized discussion about the potential benefit of a carefully tailored steroid course. The protocol did not mandate treatment, but it forced a moment of deliberate equipoise, replacing anecdotal experience with population-level probability. The study tracked over 1,200 extremely preterm neonates across a two-year period, comparing outcomes before and after the implementation of this estimator-guided pathway.

The results were striking. The rate of appropriate systemic corticosteroid therapy—defined as administration to infants who truly needed it, while sparing those at low risk—jumped from a baseline of just under 40% to more than 75% in the post-intervention period. This was not simply more steroids for everyone; the overall utilization rate did not skyrocket, confirming that the tool was sharpening precision rather than lowering the bar. Critically, the median postnatal day of first steroid administration shifted earlier, from around day 28 of life to day 19, landing squarely in a therapeutic window where animal models and observational human data suggest maximal anti-inflammatory benefit with potentially less neurotoxicity. The likelihood of discharging an infant home on supplemental oxygen, a hallmark of severe BPD, fell significantly, while short-term neurological complications did not increase—a reassuring signal that the earlier, risk-stratified approach did not inadvertently cause harm.

Beneath these headline figures lies a deeper story about the neuropharmacology of steroids in the developing brain. Glucocorticoids exert pleiotropic effects, suppressing pro-inflammatory cytokines but also interfering with neuronal migration, myelination, and cerebellar growth. The BPDe2022 tool’s genius lies in its ability to integrate not just static demographic factors but the infant’s real-time respiratory trajectory, which serves as a proxy for the intensity of pulmonary and systemic inflammation. By targeting steroids to a narrow window when inflammatory lung injury is peaking but before irreversible airway remodeling has occurred, the protocol aims to maximize the benefit-to-risk ratio. The initiative also standardized a lower-dose, shorter-duration dexamethasone regimen informed by recent pharmacokinetic modeling, further mitigating theoretical neurotoxicity while preserving efficacy on extubation and lung mechanics.

Implementation science was as crucial as the algorithm itself. The team discovered that simply displaying a risk score on an electronic dashboard changed little; behavior shifted only when the score was woven into a mandatory communication framework. The weekly “BPD risk huddle” involved neonatologists, nurse practitioners, respiratory therapists, and pharmacists, all reviewing the estimator output alongside the infant’s clinical trajectory. This collective intelligence approach dissolved the paralysis of individual risk aversion, allowing shared decision-making grounded in data. Nurses reported feeling more empowered to advocate for early intervention, while younger attending physicians found the tool invaluable in navigating disagreements with more conservative colleagues. The social architecture of the NICU, it turned out, was as modifiable as the biological one.

The study’s implications ripple far beyond neonatology. It offers a template for how predictive analytics can be translated from bench to bedside without triggering alarm fatigue or clinical inertia. The BPDe2022 tool, which is freely available online, requires no proprietary software or expensive biomarkers—only the clinical data already charted in every electronic health record. By open-sourcing the risk calculation, the NICHD inadvertently seeded a global experiment in democratized precision medicine. Community NICUs with limited resources achieved outcomes comparable to academic centers, suggesting that sophisticated risk stratification need not widen the equity gap that already plagues perinatal care. The investigators are now building a real-time, EHR-integrated version that can continuously recalculate risk as respiratory settings change, potentially allowing even more granular, day-by-day therapeutic titration.

Skeptics will rightly point out that the study lacked a contemporaneous randomized control group, relying instead on a before-and-after design that is vulnerable to secular trends. The true test of neurodevelopmental safety awaits the two-year Bayley Scale assessments, which are currently being collected. Yet for frontline clinicians who watch babies struggle on ventilators for weeks on end, the “Right Baby, Right Time” protocol has already changed the calculus of care. It replaces the haunting question “what if I cause harm?” with a more manageable one: “what does the risk estimator tell us today?” In doing so, it gives clinicians permission to act decisively when the data align, and to confidently withhold steroids when they do not. That is not just quality improvement; it is a fundamental redefinition of evidence-based courage in the NICU.

The broader lesson for medicine is unmistakable. We have spent decades developing sophisticated risk prediction models, only to leave them stranded in journal appendices. This initiative proves that the final mile of translation—embedding a model into a decision-making ritual—can be more transformative than the model’s statistical elegance. As artificial intelligence and machine learning promise ever more sophisticated forecasts, the “Right Baby, Right Time” project serves as a humbling reminder: the most powerful clinical algorithm is the one that actually changes what doctors and nurses do at 3 a.m. when a fragile set of lungs hangs in the balance.

Subject of Research: Improving timely identification of extremely preterm neonates at risk for bronchopulmonary dysplasia (BPD) and optimizing systemic corticosteroid therapy using the 2022 NICHD BPD risk estimator.

Article Title: “Right baby, right time: a multi-NICU quality improvement initiative using the 2022 NICHD BPD risk estimator to guide timely steroid therapy”

Article References: Martinez, A., Germain, A., Winners, O. et al. “Right baby, right time: a multi-NICU quality improvement initiative using the 2022 NICHD BPD risk estimator to guide timely steroid therapy”. J Perinatol (2026). https://doi.org/10.1038/s41372-026-02794-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41372-026-02794-8

Keywords: bronchopulmonary dysplasia, systemic corticosteroids, preterm neonates, risk estimator, quality improvement, NICU, NICHD BPDe2022, precision medicine, clinical decision support, neurodevelopment